These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 12804860

  • 1. Differences in immunogenicity and vaccine potential of peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase.
    Tallima H, Montash M, Veprek P, Velek J, Jezek J, El Ridi R.
    Vaccine; 2003 Jul 04; 21(23):3290-300. PubMed ID: 12804860
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and vaccine potential of dipeptidic multiple antigen peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase.
    El Ridi R, Montash M, Tallima H.
    Scand J Immunol; 2004 Oct 04; 60(4):392-402. PubMed ID: 15379864
    [Abstract] [Full Text] [Related]

  • 3. Human and murine humoral immune recognition of multiple peptides from Schistosoma mansoni glyceraldehyde 3-P dehydrogenase is associated with resistance to Schistosomiasis.
    El Ridi R, Mahrous A, Afifi A, Montash M, Velek J, Jezek J.
    Scand J Immunol; 2001 Nov 04; 54(5):477-85. PubMed ID: 11696199
    [Abstract] [Full Text] [Related]

  • 4. Peptides and multiple antigen peptides from Schistosoma mansoni glyceraldehyde 3-phosphate dehydrogenase: preparation, immunogenicity and immunoprotective capacity in C57BL/6 mice.
    Veprek P, Jezek J, Velek J, Tallima H, Montash M, El Ridi R.
    J Pept Sci; 2004 Jun 04; 10(6):350-62. PubMed ID: 15214440
    [Abstract] [Full Text] [Related]

  • 5. Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase.
    Tallima H, Dvořák J, Kareem S, Abou El Dahab M, Abdel Aziz N, Dalton JP, El Ridi R.
    PLoS Negl Trop Dis; 2017 Mar 04; 11(3):e0005443. PubMed ID: 28346516
    [Abstract] [Full Text] [Related]

  • 6. Differential protective impact of peptide vaccine formulae targeting the lung- and liver-stage of challenge Schistosoma mansoni infection in mice.
    Tallima H, Tadros MM, El Ridi R.
    Acta Trop; 2024 Jun 04; 254():107208. PubMed ID: 38621620
    [Abstract] [Full Text] [Related]

  • 7. Human T- and B-cell responses to Schistosoma mansoni recombinant glyceraldehyde 3-phosphate dehydrogenase correlate with resistance to reinfection with S. mansoni or Schistosoma haematobium after chemotherapy.
    El Ridi R, Shoemaker CB, Farouk F, El Sherif NH, Afifi A.
    Infect Immun; 2001 Jan 04; 69(1):237-44. PubMed ID: 11119511
    [Abstract] [Full Text] [Related]

  • 8. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis.
    El Ridi R, Tallima H.
    Vaccine; 2009 Jan 29; 27(5):666-73. PubMed ID: 19056448
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A DNA-prime/protein-boost vaccination regimen enhances Th2 immune responses but not protection following Schistosoma mansoni infection.
    Da'Dara AA, Skelly PJ, Walker CM, Harn DA.
    Parasite Immunol; 2003 Jan 29; 25(8-9):429-37. PubMed ID: 14651590
    [Abstract] [Full Text] [Related]

  • 11. Cysteine peptidases as schistosomiasis vaccines with inbuilt adjuvanticity.
    El Ridi R, Tallima H, Selim S, Donnelly S, Cotton S, Gonzales Santana B, Dalton JP.
    PLoS One; 2014 Jan 29; 9(1):e85401. PubMed ID: 24465551
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Egg-hatching inhibition in mice immunized with recombinant Schistosoma bovis 28 kDa glutathione S-transferase.
    Da Costa AV, Gaubert S, Lafitte S, Fontaine J, Capron A, Grzych JM.
    Parasite Immunol; 1999 Jul 29; 21(7):341-50. PubMed ID: 10417668
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Application of adult worm and lung-stage antigens to immunize against Schistosoma mansoni using cytokines as adjuvants.
    Afifi MA, El-Wakil HS, Abdel-Ghaffar MM, Mohamed RT.
    J Egypt Soc Parasitol; 2006 Apr 29; 36(1):351-62, 2p following 362. PubMed ID: 16605124
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Synthesis and characterization of a protective peptide-based vaccine against Schistosoma mansoni.
    Tarrab-Hazdai R, Schechtman D, Arnon R.
    Infect Immun; 1998 Sep 29; 66(9):4526-30. PubMed ID: 9712813
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.